Skip the chemo: Millions of breast cancer patients could be spared chemotherapy with groundbreaking genomic test

Cancer doesn’t come with just one big C — it comes with another: chemotherapy.Ask anyone just diagnosed with cancer: the question that hangs in the air is usually, “Will I need chemo?” For millions of women worldwide, the answer has traditionally been yes, even when doctors were not entirely certain how much benefit chemotherapy would provide.The treatment has saved countless lives, sure. But it’s a tough road to turn to anyway — it comes with a heavy physical and emotional cost: think hair loss, nausea, fatigue, infertility risks, nerve damage, cognitive problems, and many long-term health complications. In short, the toll goes beyond the treatment room.Now, at last, things might be about to change for a lot of patients. Per Reuters, the landmark international Optima trial has just delivered some good news: a genomic test called Prosigna can tell which women with some common forms of breast cancer probably don’t need chemo at all. The results are being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), and could shift how doctors treat patients everywhere.If experts are to be believed, this breakthrough could transform treatment decisions for thousands of patients every year in the UK and potentially millions globally.At the heart of the discovery is a growing field known as precision oncology, which is an approach that uses a tumor’s genetic characteristics to determine the most effective treatment rather than relying solely on traditional factors such as tumor size or lymph node involvement. The Prosigna test reads 50 genes in a breast tumor and sorts people into low, medium, or high risk of cancer coming back. Instead of just looking through a microscope and guessing, doctors get a blueprint of how aggressive the cancer really is.As for the Optima study, per The Guardian, it enrolled 4,400 women from the UK, Australia, Norway, Thailand, and New Zealand — all diagnosed with hormone receptor-positive, HER2-negative breast cancer (the most common kind).And here’s the heart of it: among women the test said were low risk, those who got only hormone therapy did just as well as those who got both chemo and hormone therapy. Five years later, 93.7% of women who skipped chemo were cancer-free, compared to 94.9% of those who had it, which is a difference too small to matter. So, thousands, maybe millions, of women could avoid chemo and all its misery, but keep the same chance of beating cancer.The implications are enormous because hormone receptor-positive breast cancer accounts for the majority of breast cancer cases worldwide. In fact, researchers estimate that up to two-thirds of women with this subtype could potentially be spared chemotherapy if genomic testing becomes more widely integrated into treatment planning.For starters, for many, this is quite literally life-changing. One woman in the study, Karen Bonham from Wales, reportedly learned that chemo wouldn’t do her any good, so she had only hormone therapy and radiotherapy. Nearly ten years later, she’s doing great and calls it a turning point in her life.However, doctors are careful to point out that chemo isn’t going away. Some breast cancers are aggressive, and chemo still saves lives. What’s different now is that more women can find out, with confidence, if they really need it. The genomic test is designed to determine who truly benefits from chemotherapy and who does not.Genomic testing isn’t new. In fact, tests like Oncotype DX and MammaPrint have guided treatment for a while. But the Optima trial is bigger, and for some groups (including a few with lymph node involvement), it changes the conversation.There’s another bonus: reducing unnecessary chemo means fewer cases of long-term side effects — think heart problems, nerve injuries, trouble with memory, cognitive side effects sometimes referred to as “chemo brain”, and the rest. Moreover, it saves money.More importantly, this is part of a bigger shift. Cancer care is becoming more personal, more targeted: the right treatment tailored for the right person, no more, no less.